You have access
Safety and Efficacy of RAD001 (Everolimus) Administered Upon Relapse During or After Adjuvant Treatment in Post-menopausal Women With Hormone Receptor Positive, HER2/neu Negative Locally Advanced or Metastatic Breast Cancer (CRAD001JGR08 “MELPOMENI” study)
ATHANASIOS ALEXOPOULOS, CHARISIOS KARANIKIOTIS, ALEXANDROS ARDAVANIS, IOANNIS BOUKOVINAS, PARISIOS MAKRANTONAKIS, CHRISTOS PAPADIMITRIOU, ATHANASIOS ATHANASIADIS, ANASTASIOS BOUTIS, STYLIANOS GIASSAS, STYLIANOS KAKOLYRIS, GEORGIOS KOUMAKIS, KONSTANTINOS PAPAZISIS, ADAMANTIA PSYRRI, NIKOLAOS ZIRAS, SOFIA BAKA, NIKOLAOS KENTEPOZIDIS and VASILIKI MICHALAKI
Anticancer Research February 2022, 42 (2) 1031-1041; DOI: https://doi.org/10.21873/anticanres.15564